• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Zenas BioPharma

Zenas BioPharma is developing immune-based therapies for autoimmune and rare diseases. 

target reach ladder climb meet win beat competition
Biotech

Zenas autoimmune drug prompts 95% drop in lesions in MS study

Zenas Biopharma’s lead autoimmune drug has been tied to a 95% reduction in a type of brain lesions over 12 weeks in a phase 2 MS study.
James Waldron Oct 27, 2025 9:25am
gems jewels crown diamonds rocks

Royalty bestows Zenas with $300M for autoimmune approval push

Sep 2, 2025 11:07am
Paraglider over a snowy mountain

J&J innovator vaults to Valo—Chutes & Ladders

Apr 11, 2025 8:30am
parachute chutes

Former FDA deputy joins AI biotech's board—Chutes & Ladders

Mar 21, 2025 8:30am
gold arrow pointing upward forward

Biophama VC, deal values and exits all rise in Q3: Pitchbook

Nov 20, 2024 6:15am
Graphic image of the letters IPO in white in front of a yellow background

Zenas, MBX, Bicara head to Nasdaq in hot day for biotech IPOs

Sep 13, 2024 5:25am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings